ID

42334

Description

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01316224

Link

https://clinicaltrials.gov/show/NCT01316224

Keywords

Versions (2)
  1. 6/15/21 6/15/21 -
  2. 6/15/21 6/15/21 -
Copyright Holder

AbbVie (prior sponsor, Abbott)

Uploaded on

June 15, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

English
Details

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

1 forms  
Inclusion Criteria
participant has a documented clinical diagnosis of psoriasis, as determined by participant interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator
participant has indication of psoriasis systemic therapy
if female, participant is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine device (iud)
contraceptives (oral or parenteral) for three months (90 days) prior to study drug administration
a vasectomized partner
total abstinence from sexual intercourse
able and willing to give written informed consent and comply with the requirements of the study protocol
Exclusion Criteria
participants who have active infections
participants enrolled in another study or clinical trial
any condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or participants to an unacceptable risk
history of active tuberculosis (tb), histoplasmosis or listeriosis
Back to the top of the page

Similar models

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial